Neuromuscular Blocking Drugs

Correct Answer

B — Succinylcholine

Rationale

Succinylcholine is classified as an ultrashort-acting neuromuscular blocking drug, with a duration of action of approximately 5 to 10 minutes after a standard intubating dose. This brief duration results from rapid hydrolysis by plasma cholinesterase in the bloodstream. Rocuronium and vecuronium are intermediate-acting nondepolarizing agents with durations of approximately 25 to 40 minutes. Pancuronium is a long-acting nondepolarizing agent with a duration of 60 to 90 minutes or longer.

Correct Answer

D — Rocuronium

Rationale

Rocuronium is classified as the preferred nondepolarizing alternative for rapid sequence intubation when succinylcholine is contraindicated — for example, in patients with hyperkalemia risk, malignant hyperthermia susceptibility, or known pseudocholinesterase deficiency. At high doses, rocuronium achieves intubating conditions more rapidly than other nondepolarizing agents, and its block can be rapidly reversed by sugammadex even at high doses, providing a rescue strategy in a failed-intubation scenario. Pancuronium is long-acting and has a vagolytic cardiovascular profile that limits its use for rapid sequence intubation. Atracurium undergoes Hofmann elimination and is preferred in organ failure but is not the rapid sequence intubation alternative. Mivacurium is the shortest-acting nondepolarizing agent but does not achieve intubating conditions rapidly enough to substitute for succinylcholine in this role.

Correct Answer

A — Volatile inhalational anesthetics

Rationale

Volatile inhalational anesthetics — including halothane, sevoflurane, desflurane, and isoflurane — are classified as trigger agents for malignant hyperthermia, along with succinylcholine. In genetically susceptible individuals, either class of agent can precipitate the syndrome. Anticholinesterase agents such as neostigmine are reversal drugs for nondepolarizing neuromuscular block and are not malignant hyperthermia triggers. Nondepolarizing neuromuscular blocking drugs do not trigger malignant hyperthermia. Total intravenous anesthetic agents — such as propofol — are classified as non-triggering alternatives and are the preferred agents for anesthesia in malignant hyperthermia-susceptible patients.

Correct Answer

C — Mivacurium

Rationale

Mivacurium is the only short-acting nondepolarizing neuromuscular blocking drug, with a duration of approximately 15 to 20 minutes in patients with normal plasma cholinesterase activity — the enzyme responsible for its metabolism. Among nondepolarizing agents it occupies the shortest-duration category. Vecuronium and rocuronium are both intermediate-acting nondepolarizing agents with durations of approximately 25 to 40 minutes. Cisatracurium is an intermediate-acting agent that undergoes Hofmann elimination, with a similar duration to vecuronium and rocuronium.

Correct Answer

B — Propofol

Rationale

Propofol is classified as a total intravenous anesthetic agent. In patients with malignant hyperthermia susceptibility, all volatile inhalational anesthetics are contraindicated because they are classified as trigger agents for the syndrome. Propofol does not trigger the ryanodine receptor defect and is therefore the preferred anesthetic for maintenance of anesthesia in these patients. Sevoflurane, halothane, and desflurane are all volatile inhalational anesthetics — they belong to the trigger-agent class and are absolutely contraindicated in malignant hyperthermia-susceptible patients.

Correct Answer

D — Dibucaine

Rationale

Dibucaine is a local anesthetic that is used in the dibucaine number test — a laboratory assay that measures how much dibucaine inhibits a patient's plasma cholinesterase. Normal plasma cholinesterase is strongly inhibited by dibucaine, producing a high dibucaine number. The atypical enzyme found in pseudocholinesterase deficiency is far less inhibited by dibucaine, producing a low dibucaine number. This test identifies patients at risk for prolonged succinylcholine paralysis before they are exposed to the drug. Neostigmine is an anticholinesterase reversal agent. Succinylcholine is the depolarizing neuromuscular blocking drug whose metabolism depends on plasma cholinesterase. Dantrolene is the specific treatment for malignant hyperthermia.

Correct Answer

C — Succinylcholine is hydrolyzed by plasma cholinesterase — a circulating enzyme distinct from acetylcholinesterase — which rapidly cleaves it to inactive metabolites in the bloodstream

Rationale

Succinylcholine is metabolized by plasma cholinesterase — also called pseudocholinesterase — a liver-produced enzyme that circulates in the plasma throughout the body. Plasma cholinesterase cleaves succinylcholine first to succinylmonocholine and then to succinic acid and choline, both pharmacologically inactive. This hydrolysis occurs rapidly in the plasma, so succinylcholine is being destroyed before, during, and after its brief transit through the neuromuscular junction — producing the characteristic 5 to 10 minute duration. Plasma cholinesterase is entirely distinct from acetylcholinesterase, which is anchored at the neuromuscular junction and synaptic membranes and terminates acetylcholine signaling. Spontaneous chemical degradation at physiologic conditions describes Hofmann elimination — the mechanism of atracurium and cisatracurium, not succinylcholine. Adipose redistribution does not play a meaningful role in terminating succinylcholine's effect.

Correct Answer

A — Its onset of intubating conditions within 60 seconds minimizes the time the airway is unprotected, and its brief duration allows spontaneous ventilation to resume if intubation fails

Rationale

Succinylcholine produces complete intubating conditions — full jaw relaxation and vocal cord opening — within 60 seconds, faster than any other neuromuscular blocking drug at standard doses. This rapid onset minimizes the window between loss of consciousness and placement of a cuffed endotracheal tube, which is critical in patients at risk for aspiration. Equally important, if intubation fails after succinylcholine, the brief duration of 5 to 10 minutes means paralysis resolves spontaneously and the patient can resume spontaneous ventilation. A long-acting nondepolarizing agent in a failed-intubation scenario can leave the patient apneic for 30 to 60 minutes — precisely the opposite of what rapid sequence intubation requires. Succinylcholine has no reversal agent for phase I block; neostigmine cannot accelerate its metabolism and would worsen the block. Succinylcholine produces flaccid paralysis of all muscles including glottic muscles — it does not maintain glottic tone.

Correct Answer

D — Patients with burns, crush injury, denervation, or prolonged immobilization are at risk because these conditions trigger extrajunctional receptor upregulation, which requires time to develop — leaving the first 24 hours safe before upregulation occurs

Rationale

Burns, crush injury, denervation from any cause (spinal cord injury, stroke, peripheral nerve injury), and prolonged immobilization all disrupt the normal relationship between the motor nerve and the muscle fiber. In response, the muscle upregulates nicotinic acetylcholine receptors across the entire extrajunctional surface. When succinylcholine is given to these patients, it activates the vastly expanded receptor population and triggers massive potassium efflux sufficient to cause ventricular fibrillation. Upregulation requires time to develop — it is not present in the immediate aftermath of injury. In the first 24 hours after an acute burn or crush injury, extrajunctional receptors have not yet appeared, and succinylcholine can be used safely for emergency airway management. After this window, the risk escalates and persists for as long as the underlying condition remains. Renal failure and anticholinesterase medications do not produce this upregulation-driven hyperkalemia. Malignant hyperthermia involves calcium release from the sarcoplasmic reticulum through the ryanodine receptor — a distinct mechanism unrelated to extrajunctional receptor upregulation.

Correct Answer

B — A defect in the ryanodine receptor causes uncontrolled calcium release from the sarcoplasmic reticulum; dantrolene inhibits the ryanodine receptor and blocks further calcium release

Rationale

Malignant hyperthermia susceptibility is caused by an inherited defect in the ryanodine receptor — the calcium release channel in the sarcoplasmic reticulum of skeletal muscle. In susceptible patients, exposure to succinylcholine or a volatile inhalational anesthetic causes the ryanodine receptor to open uncontrollably, flooding the muscle cytoplasm with calcium. The resulting sustained muscle contraction and hypermetabolic state consumes adenosine triphosphate at an enormous rate, generating massive heat, consuming oxygen, and producing carbon dioxide and lactic acid at a rate that overwhelms normal physiology. Dantrolene is the specific antidote: it acts directly on the ryanodine receptor, inhibiting calcium release from the sarcoplasmic reticulum and halting the runaway activation. The defect is not in plasma cholinesterase, acetylcholinesterase, or mitochondrial calcium handling, and dantrolene does not act on nicotinic receptors or voltage-gated calcium channels in the muscle membrane.

Correct Answer

C — Without plasma cholinesterase to hydrolyze it, succinylcholine persists in the circulation and continues to block neuromuscular transmission; no reversal agent exists because neostigmine cannot accelerate succinylcholine clearance and would worsen the block

Rationale

Succinylcholine's ultrashort duration depends entirely on its rapid hydrolysis by plasma cholinesterase. In homozygous pseudocholinesterase-deficient patients, this enzyme is absent or severely reduced, so succinylcholine is not cleared at the normal rate and persists in the circulation for 2 hours or longer, maintaining continuous depolarizing block at the neuromuscular junction. There is no pharmacological reversal agent for this situation. Neostigmine inhibits acetylcholinesterase — a different enzyme from plasma cholinesterase — and would raise acetylcholine levels, which cannot repolarize an already-depolarized end plate and would prolong the block further by inhibiting whatever residual plasma cholinesterase activity remains. Management is mechanical ventilation until succinylcholine is eventually eliminated through minor alternative pathways. Succinylcholine does not produce irreversible receptor binding, and its prolongation in this condition is not due to renal excretion or metabolite accumulation.

Correct Answer

A — The test measures how much dibucaine inhibits the patient's plasma cholinesterase; normal enzyme is strongly inhibited (high number), while the atypical enzyme is poorly inhibited (low number), predicting prolonged succinylcholine metabolism

Rationale

The dibucaine number is a functional assay, not a concentration measurement or a genetic sequencing test. Dibucaine — a local anesthetic — inhibits normal plasma cholinesterase strongly, producing a high dibucaine number (approximately 70 to 80 in homozygous normal individuals). The atypical enzyme found in pseudocholinesterase deficiency is structurally different and is inhibited far less by dibucaine, producing a low dibucaine number (approximately 20 in homozygous atypical individuals). Heterozygous individuals show intermediate values. A low dibucaine number identifies the atypical enzyme and predicts that succinylcholine will be hydrolyzed poorly, resulting in prolonged paralysis. The test measures inhibition of enzyme activity by dibucaine — not the rate of dibucaine metabolism, not the total enzyme concentration, and not the genetic sequence directly.

Correct Answer

D — Severe liver disease, pregnancy, organophosphate exposure, and echothiophate eye drops each reduce plasma cholinesterase activity through different mechanisms — impaired synthesis, decreased levels, or enzyme inhibition — modestly prolonging succinylcholine duration

Rationale

Plasma cholinesterase is synthesized by the liver and circulates in the blood throughout the body. Severe liver disease impairs enzyme synthesis, reducing circulating levels. Pregnancy also decreases plasma cholinesterase concentration, though usually not to a degree that produces clinically significant prolongation in most patients. Organophosphate compounds and echothiophate eye drops — used for glaucoma — inhibit plasma cholinesterase enzymatically, reducing its ability to hydrolyze succinylcholine. In all of these settings, succinylcholine is metabolized more slowly, prolonging its duration modestly compared to the dramatic 2-hour or longer apnea seen in homozygous pseudocholinesterase deficiency. The prolongation in these acquired states typically resolves with continued ventilatory support over a predictable time course. Aminoglycosides do potentiate nondepolarizing neuromuscular block — a real and clinically significant interaction — but through presynaptic inhibition of calcium-dependent acetylcholine release and a direct postjunctional blocking effect, not through inhibition of plasma cholinesterase. Calcium channel blockers similarly act at the presynaptic terminal. Neither class inhibits plasma cholinesterase, so neither prolongs succinylcholine through the mechanism stated in option C. Renal failure and thyroid disease do not reduce plasma cholinesterase activity through any recognized mechanism.

Correct Answer

B — Sugammadex encapsulates rocuronium molecules directly in the plasma at any depth of block, rapidly reducing free rocuronium concentration and allowing neuromuscular transmission to recover within minutes

Rationale

Sugammadex is a modified cyclodextrin that captures rocuronium molecules in the plasma with extremely high affinity, forming a stable inactive complex. As free rocuronium is removed from the plasma by sugammadex, the drug dissociates from nicotinic receptors at the neuromuscular junction and diffuses into the plasma, where it is immediately captured. This encapsulation mechanism reverses rocuronium block at any depth — including complete block with no detectable train-of-four twitches — within minutes, without requiring any spontaneous recovery. In a failed intubation after high-dose rocuronium, sugammadex can restore neuromuscular function rapidly, giving the patient time to resume spontaneous ventilation. Succinylcholine's offset relies on spontaneous plasma cholinesterase hydrolysis and cannot be pharmacologically accelerated. Sugammadex does not inhibit acetylcholinesterase and does not stimulate receptor upregulation. Rocuronium undergoes biliary elimination, not Hofmann elimination, and does not offset in 10 minutes at high doses.

Correct Answer

C — Severe liver disease impairs synthesis of plasma cholinesterase, the enzyme responsible for succinylcholine hydrolysis, reducing the rate at which the drug is cleared from the circulation

Rationale

Plasma cholinesterase — the enzyme that hydrolyzes succinylcholine to inactive metabolites — is synthesized by the liver. In patients with severe hepatic disease, enzyme production is impaired, circulating plasma cholinesterase levels are reduced, and succinylcholine is metabolized more slowly than normal. The drug persists in the circulation, continues to reach the neuromuscular junction, and prolongs block well beyond the expected 5 to 10 minutes. The prolongation in acquired liver disease is typically moderate compared to the 2-hour or longer paralysis seen in genetic pseudocholinesterase deficiency, and it resolves with continued ventilatory support. End-stage liver disease does not cause nicotinic receptor upregulation — that is the consequence of denervation and muscle injury. Succinylcholine is not renally excreted in a clinically significant amount, and bilirubin does not competitively inhibit succinylcholine at the receptor.

Correct Answer

A — Rocuronium for neuromuscular blockade and propofol for anesthesia maintenance

Rationale

In patients with malignant hyperthermia susceptibility, both succinylcholine and all volatile inhalational anesthetics — including sevoflurane, halothane, desflurane, and isoflurane — are classified as trigger agents and are absolutely contraindicated. Exposure to either class can precipitate a life-threatening hypermetabolic crisis through uncontrolled ryanodine receptor activation. Rocuronium is a nondepolarizing neuromuscular blocking drug with no ryanodine receptor activity and does not trigger malignant hyperthermia. Propofol is a total intravenous anesthetic agent that does not interact with the ryanodine receptor and is the preferred agent for anesthesia maintenance in these patients. Options containing succinylcholine are contraindicated regardless of the anesthetic used. Options containing sevoflurane are contraindicated regardless of the neuromuscular blocking drug used. Only the combination of a non-triggering neuromuscular blocking drug with a non-triggering anesthetic is safe.

Correct Answer

D — The patient has pseudocholinesterase deficiency — a genetic absence of functional plasma cholinesterase — so succinylcholine is not hydrolyzed at the normal rate; there is no reversal agent, and management requires continued mechanical ventilation

Rationale

Apnea lasting 2 hours or longer after a standard succinylcholine dose is the clinical hallmark of homozygous pseudocholinesterase deficiency. In these patients, the plasma cholinesterase gene carries an atypical variant that produces an enzyme with severely reduced or absent activity against succinylcholine. Without the enzyme to hydrolyze it, succinylcholine persists in the circulation and maintains depolarizing block at the neuromuscular junction far beyond the expected 5 to 10 minutes. There is no pharmacological reversal agent: anticholinesterases such as neostigmine inhibit acetylcholinesterase — a different enzyme — and would worsen the block. Sugammadex encapsulates rocuronium and vecuronium only; it has no binding affinity for succinylcholine and provides no reversal in this setting. Management is mechanical ventilation until succinylcholine is cleared through minor alternative pathways. Phase II block from a single standard dose is not expected and does not account for a 2.5-hour duration. Unrecognized liver disease produces moderate prolongation — not 2.5-hour apnea from a single standard dose.

Correct Answer

B — Rocuronium, because major burn injury causes persistent extrajunctional receptor upregulation that makes succinylcholine administration dangerous due to the risk of life-threatening hyperkalemia

Rationale

Major burn injury triggers upregulation of nicotinic acetylcholine receptors across the entire extrajunctional muscle surface beginning within 24 to 48 hours of the injury. At three weeks post-burn, upregulation is well established and persists for as long as the burns remain unhealed. Succinylcholine administered in this setting activates the vastly expanded receptor population simultaneously, causing massive potassium efflux from muscle cells throughout the body — sufficient to cause ventricular fibrillation and cardiac arrest. Succinylcholine is contraindicated from approximately 24 to 48 hours after a major burn and remains contraindicated until healing is complete. Rocuronium is the appropriate alternative for rapid sequence intubation in this patient, with sugammadex available for reversal if needed. Extrajunctional upregulation does not resolve within 2 weeks — it persists as long as denervation or injury is present. Burn injury reduces plasma cholinesterase modestly but does not make succinylcholine safer; the upregulation-driven hyperkalemia risk is the decisive contraindication. Mivacurium is metabolized by plasma cholinesterase and is not designed for rapid sequence intubation indications.